YolTech, a clinical-stage biopharmaceutical company specializing in mRNA-LNP delivery for in vivo gene editing therapies, has partnered with KACTUS, a leading developer serving the biopharmaceutical industry, to advance the commercialization of YolTech's proprietary DNA editor, YolCas12^TM, in Greater China. Under this agreement, KACTUS gains exclusive rights for the production and sale of YolCas12^TM.

YolCas12^TM represents a breakthrough in molecular-level targeted modifications, offering unparalleled accuracy and efficiency. This technology holds tremendous potential for diverse applications, including gene therapy and biomedical research which has been validated by multiple collaborative companies. Currently, TolTech has applied this editor to enter the clinical trial stage.

"We are excited to announce this collaboration with KACTUS, which underscores our leadership in genetic innovation," said Dr. Yuxuan Wu, Founder and CEO of YolTech. "This milestone reflects our commitment to advancing in vivo gene editing and our dedication to improving patient outcomes."

Mr. Gang Wang, Founder and CEO of KACTUS, added, " We are excited to integrate YolTech's leading gene editing tools with KACTUS's commercial capabilities, enhancing accessibility to advanced therapies."